

SCHIRMACHER, PROF. DR. PETER (M)

(*04.11.1961)



DIRECTOR

Institute of Pathology
University Hospital
Im Neuenheimer Feld 224
69120 Heidelberg

Phone: ++49/6221/56 4160

Email: peter.schirmacher@med.uni-heidelberg.de**ACADEMIC EDUCATION AND SCIENTIFIC DEGREES**

1989-1991	Postdoctoral Research Fellowship (DFG) and PhD-Study (Molecular Biology), Liver Res. Center, Albert Einstein College of Med., New York
1987-1998	Institute of Pathology, University of Mainz
1987	MD-Thesis, Institute of Physiology, University Mainz (Grade: magna cum laude, supervised by Prof. Dr. R. Zander)
1981-1987	Study of Medicine, University of Mainz

PROFESSIONAL CAREER

since 2004	Professor of Pathology (C4) and Director, Inst. of Pathology, Heidelberg
1998-2004	Professor of Pathology (C3), Deputy Director, Inst. of Pathology, Cologne
1996	Board Certification Molecular Pathology and Habilitation (supervised by Prof. Dr. Dr. C.J. Kirkpatrick)
1995	Board Certification Pathology
since 1992	Research Group leader

OTHERS

Since 2014	Board Member German Telematics Platform
since 2013	Board Member International Liver Cancer Association (ILCA)
since 2013	Chairman German Society of Pathology
2012-2013	President German Society of Pathology
2011-2012	President International Laennec Society of Liver Pathology
since 2011	Board Member German Liver Foundation
since 2011	Founder and Coordinator of the centralized BiomaterialBank Heidelberg BMBH
since 2011	Principle Investigator and Coordinator of Biobanking Platforms, German Consortium for Translational Cancer Research (DKTK) and German Center for Infectious Diseases Research (DZIF)
since 2010	Coordinator of the SFB/TRR77 "Liver Cancer"
since 2008	Member and Speaker (2008-2012) of Section 2 (Cancer and Stem Cell Research), DFG Fachkollegiat
2007-2009	Board Member German Association for Study of the Liver (President 2008-2009)
since 2007	Board Member German Association of Pathology
since 2006	Co-Founder and Speaker of the Advisory Board 'Tissue Imaging and Analysis Center' (TIGA), Heidelberg

OTHERS

since 2005	Founder and Speaker 'Tissue Bank of the National Center of Tumor Diseases' Founder and Speaker 'Working Group Tissue Banks of the German Cancer Centers'
2004-2010	Managing board Tumorzentrum Heidelberg/Mannheim
2001-2004	Managing board 'Center for Molecular Medicine Cologne' (CMMC)
1996-1998	Managing board DFG-SFB 519
Editorial Boards:	Journal of Hepatology (Associate Editor), Hepatology, Virchows Archive, Liver Cancer, Pathology Research and Practice, Pathologie

AWARDS AND APPOINTMENTS

Since 2012	Member of the Leopoldina, German National Academy of Sciences
1997	Boehringer Ingelheim Award
1987	Johannes Gutenberg Award

FIELDS OF INTEREST

Molecular and morphological digestive tract carcinogenesis (especially liver and pancreas); Tumorigenic role of growth factor mediated signaling processes; Chronic liver diseases and their role in hepatocarcinogenesis; molecular pathological diagnostics; Biobanking; Virtual Microscopy

SELECTED PUBLICATIONS

1. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies mechanisms of Sorafenib resistance in liver cancer. *Nat Med.* 20(10):1138-46.
2. Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-Pons A, Breuhahn K, Longerich T, Bermejo JL, Gretz N, Zender L, Schirmacher P, Beck M, Singer S (2014) Prosurvival function of the cellular apoptosis susceptibility/importin- α 1 transport cycle is repressed by p53 in liver cancer. *Hepatology* 60(3):884-95.
3. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C (2012) Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. *Mol Cell* 48(5):799-810.
4. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* 479(7374):547-51.
5. Breuhahn K, Gores G, Schirmacher P (2011) Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. *Hepatology* 53(6):2112-21.